조혈모세포이식 후 구강 내 이식편대숙주반응 치료에 사용된 Cyclosporine액의 국소적용 사례보고
Case Report on the Use of Cyclosporine solution for the treatment of Oral Graft versus host disease (GVHD) after BMT
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Abstract : Graft versus host disease (GVHD) is an important cause of morbidity and mortality in hematopoietic stem cell transplantation patients. Patients with oral GVHD may develop symptomatic severe oral ulceration, erythema, lichenoid and lupus-like changes, in addition to the dryness of the oral mucosa, due to involvement of the salivary glands. A combined use of cyclosporine or tacrolimus and methotrexate is a principal approach for prevention of GVHD. Corticosteroid is used as the first-line therapy, but clinical effects of the other treatments have not been proven yet. Moreover, there are possibilities of the adverse effects induced from systemic use of corticosteroids and immunosuppressive agents, thus, the need of adjuvant local therapies emerged. In this case report, we described the management of oral GVHD with topical cyclosporine solution. A 53-year-old female, diagnosed as Acute myeloid leukemia (AML), received an allogenic hematopoietic stem cell transplantation (HSCT) and developed GVHD, involving skin, gut and oral cavity. Management included systemic corticosteroids and topical agents, such as normal saline and chlorhexidine, to relieve oral symptoms. However, it did not show a significant improvement. The patient was readmitted for GVHD and cytomegalovirus retinitis after being discharged. At this point, oral GVHD was estimated as a total score of 10, the sum of erythema 3, linchenoid 1,ulceration 6 and mucoceles 0, by the National Institutes of Health (NIH) consensus scoring system with numerical rating scale (NRS) of 10 for pain. The patient was decided to use cyclosporine solution as an oral rinse in the condition of oral intake restriction due to bleeding tendency. We opted for the patient to use the cyclosporine solution. Oncology pharmacist instructed the patient to rinse the mouth with 5ml of cyclosporine solution for 5 minutes, three times a day. After two weeks, the application of cyclosporine mouth rinse resulted in an improvement of the oral GVHD;total score of 4 presented, as the sum of erythema 1, linchenoid 0, ulceration 3 and mucoceles 0,with NRS 4 in the pain. Application of cyclosporine mouth rinse is considered to be a remedy for oral GVHD to minimize the adverse effects induced from systemic therapy and to maximize curative value.
Abstract
Abstract : Graft versus host disease (GVHD) is an important cause of morbidity and mortality in hematopoietic stem cell transplantation patients. Patients with oral GVHD may develop symptomatic severe oral ulceration, erythema, lichenoid and lupus-like changes, in addition to the dryness of the oral mucosa, due to involvement of the salivary glands. A combined use of cyclosporine or tacrolimus and methotrexate is a principal approach for prevention of GVHD. Corticosteroid is used as the first-line therapy, but clinical effects of the other treatments have not been proven yet. Moreover, there are possibilities of the adverse effects induced from systemic use of corticosteroids and immunosuppressive agents, thus, the need of adjuvant local therapies emerged. In this case report, we described the management of oral GVHD with topical cyclosporine solution. A 53-year-old female, diagnosed as Acute myeloid leukemia (AML), received an allogenic hematopoietic stem cell transplantation (HSCT) and developed GVHD, involving skin, gut and oral cavity. Management included systemic corticosteroids and topical agents, such as normal saline and chlorhexidine, to relieve oral symptoms. However, it did not show a significant improvement. The patient was readmitted for GVHD and cytomegalovirus retinitis after being discharged. At this point, oral GVHD was estimated as a total score of 10, the sum of erythema 3, linchenoid 1,ulceration 6 and mucoceles 0, by the National Institutes of Health (NIH) consensus scoring system with numerical rating scale (NRS) of 10 for pain. The patient was decided to use cyclosporine solution as an oral rinse in the condition of oral intake restriction due to bleeding tendency. We opted for the patient to use the cyclosporine solution. Oncology pharmacist instructed the patient to rinse the mouth with 5ml of cyclosporine solution for 5 minutes, three times a day. After two weeks, the application of cyclosporine mouth rinse resulted in an improvement of the oral GVHD;total score of 4 presented, as the sum of erythema 1, linchenoid 0, ulceration 3 and mucoceles 0,with NRS 4 in the pain. Application of cyclosporine mouth rinse is considered to be a remedy for oral GVHD to minimize the adverse effects induced from systemic therapy and to maximize curative value.
참고문헌 (20)
- Snover D.C, "Acute and chronic graft versus host disease : histopathological evidence for two distinct pathogenetic mechanisms", Hum Pathol, 15, pp.202~205 (1984)
- Aschan J.A, "Individualized prophylaxis against graft-versus-host disease in leukemic marrow transplant recipients", Bone Marrow Transplant, 14, pp.79~87 (1994)
- Woo S.B, "Graft-vs.-host disease", Crit Rev Oral Biol Med, 8, pp.201~216 (1997)
- Nakamura S, "Oral involvement in chronic graftversus- host disease after allogeneic bone marrow transplantation", Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 82, pp.556~563 (1996)
- Mark M. Schubert, "DDS, MSD, Maria Elvira Pizzicatti Correa, DDS, MSD, PhD : Oral Graft-Versus-Host Disease", Dent Clin N Am, 52, pp.79~109 (2008)
- CRISTIANE MIRANDA FRANCA, "Graft-vs.- host disease Severe oral manifestations of chronic", J Am Dent Assoc, 132, pp.1124~1127 (2001)
- Schwinghammer T.L, "Pharmacologic prophylaxis of acute graft-versus-host disease after allogeneic marrow transplantation", Clin Pharm, 12, pp.736~761 (1993)
- Iwasaki T, "Recent advances in the treatment of graft-versus-host-disease", Clin Med Res, 2, pp.243~252 (2004)
- Robert A. Utsman, "Budesonide for local therapy of complex oral mucosal immune- mediated inflammatory diseases: case reports", Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 106, pp.11~17 (2008)
- Ismail Sari, "The effect of Budesonide Mouthwash on Oral Chronic Graft Versus Host Disease", American Journal of Hematology, 82, pp.349~356 (2007)
- Elad S, "Budesonide : a novel treatment for oral chronic graft versus host disease", Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 95, pp.308~311 (2003)
- Epstein J.B, "Topical azathioprine in the treatment of immune-mediated chronic oral inflammatory conditions", Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 91, pp.56~61 (2001)
- Epstein J.B, "Topical cyclosporin A for treatment of oral chronic graft-versus-host disease", Bone Marrow Transplant, 13, pp.81~86 (1994)
- Andres R. Sanchez, "Successful treatment of oral lichen planus-like cGvHD with topical tacrolimus:a case report", J Periodontol, 75, pp.613~619 (2004)
- Andre Eckardt, "Severe oral cGvHD following allogeneic bone marrow transplantation highly effective treatment with topical tacrolimus", Oral Oncology, 40, pp.811~814 (2004)
- Redding S.W, "Treatment of oral chronic graft-versus-host disease with PUVA therapy: case report and literature review", Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 13, pp.81~86 (1994)
- Elad S, "Ultraviolet B irradiation, A new therapeutic concept for the management of oral manifestations of graftversus host disease", Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 86, pp.183~187 (1998)
- Pavletic S.Z, "Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus- Host Disease : IV. Response Criteria Working Group report", Biol Blood Marrow Transplant, 12, pp.252~266 (2006)
- G.M. Pereira, "Mechanism of action of cyclosporine A in vivo. II. T cell priming in vivo to alloantigen can be mediated by an IL-2-independent cyclosporine Aresistant pathway", The Journal of Immunology, 144(6), pp.2109~2116 (1990)
- Epstein J.B, "Topical cyclosporine in a bioadhesive for treatment of oral lichenoid mucosal reactions: an open label clinical trial", Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 82, pp.532~536 (1996)